Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amag

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

Vertex reports fatal reactions with hepatitis C drug

Adds boxed warning to Incivek

- PMLiVE

Lundbeck and Takeda submit depression drug for US approval

Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex

- PMLiVE

Interview: Trevor Smith, Takeda

Takeda’s head of commercial operations for Europe and Canada talks about the integration of Nycomed and European market access

- PMLiVE

Takeda acquires US-based drug discovery company Envoy

Japanese pharma firm gains target identification technology and preclinical CNS assets

Novartis building

Canada and Switzerland lift Novartis flu vaccines ban

Independent tests confirm safety following contamination fears

- PMLiVE

Acquisitions soften Actos blow in Takeda’s first-half results

URL Pharma and Nycomed purchases help sales increase 12 per cent to 787bn yen

Novartis building

France, Germany and Spain join list of countries banning Novartis vaccines

Flu vaccines Agrippal and Fluad withdrawn after some batches found to be contaminated

- PMLiVE

FDA panel backs Sanofi’s Kynamro for high cholesterol

Recommendation comes despite safety concerns

- PMLiVE

Abbott stops kidney disease drug trial on safety concerns

Concerns about excess serious adverse events and mortality in patients taking bardoxolone methyl

- PMLiVE

Death toll reaches 19 in US meningitis outbreak

Victims exposed to contaminated drugs

Pharma must ’embrace the new reality’ and meet payers’ needs

This means capturing better health economic data during product development, says Takeda's Trevor Smith

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links